© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
(Reuters) – AstraZeneca (NASDAQ:) said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union.
Be the first to comment